eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
3/2010
vol. 48
 
Share:
Share:
more
 
 

Review article
Brain lesions in tuberous sclerosis complex. Review

Wiesława Grajkowska
,
Katarzyna Kotulska
,
Elżbieta Jurkiewicz
,
Ewa Matyja

Folia Neuropathol 2010; 48 (3): 139-149
Online publish date: 2010/10/04
Article file
- Brain lesions.pdf  [0.50 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

Tuberous sclerosis complex (TSC) is an autosomal dominant, multisystem disease with high penetrance and variability. Its incidence is estimated to be as high as 1 : 6000 [1,6,7]. TSC is characterized by the deve­lopment of multiple hamartomas and benign or rarely malignant neoplasms distributed at various sites throughout the body, especially in the brain, skin, retina, kidney, heart, and lungs [6,7,14,15,18]. Cutaneous lesions include angiofibromas, localized cutaneous thickenings (shagreen patches), hypopigmented macules (“ash-leaf” patches) or spots (confetii-like lesions) and ungual or periungual fibromas known as Koenen’s tumours. Brain lesions in TSC include: cortical/subcortical and subcortical tubers, subependymal nodules (SEN), and subependymal giant cell astrocytomas (SEGA), as well as white matter lesions [24,30]. The individuals with TSC can also develop renal and liver angiomyolipoma, renal clear cell carcinoma, retinal glial hamartomas, cardiac rhabdomyomas and pulmonary lymphangioleiomyomatosis (LAM) or multifocal micronodular hyperplasia of type II pneumocytes [26]. Cysts may be found in various locations, including the liver, kidneys and pancreas [17,27]. ­ Va­rious vascular lesions, including aneurysms may be found in brain and other locations in TSC patients [14,15]. In 1998, the specific clinical diagno­stic criteria for TSC were established and divided into two main categories: major and minor (Table I) [26]. In children with TSC, the brain lesions are the major causes of morbidity and mortality. The majority of TSC patients present with epilepsy, beginning in early childhood, cognitive impairment, autism spectrum disorders, and sleep disorders [18].

Radiologic features of brain lesions

Brain lesions in TSC include cortical tubers, subependymal nodules, radial hypomyelinated tracts extending from subependymal area to the cortex, and subependymal giant cell astrocytomas (SEGAs). The MRI pattern of these lesions changes with the age of patients.

Cortical tubers

They are mostly supratentorial, although 8-15% of patients with TSC develop infratentorial cerebellar tubers. In neonates and young infants cortical tubers have high signal on T1-weighted images (WI) and low on T2-WI compared to the unmyelinated white mater [2]. In older children and adult patients the tubers appear hypointense on T1-WI and hyperintense on T2-WI and FLAIR images (Fig. 1). Most of the affected gyri are enlarged. Some of them present cyst-like changes: FLAIR sequences typically show central signal loss with a high signal peripheral rim [17,27]. The cause of the cystic changes is unknown but these changes might reflect cellular degeneration. It is more commonly seen in children younger than 7 years.
About half of cortical tubers calcify, which is well seen on CT images. On MR images, the large calcified lesions show significant signal loss on T2-WI and T2*WI (gradient echo sequences) [4]. Calcification incidence also increases with age, it is rare in infants. The tubers exhibit contrast enhancement in approximately 3-4% of cases. Unlike cortical tubers, the cerebellar tubers are usually wedge-shaped.
Proton spectroscopy of tubers shows a decrease of N-acetylaspartate (NAA) and increased myo-inositol, which confirms a reduction of neurons, gliosis, or the presence of immature neurons [2].

Subependymal nodules

Subependymal nodules occur along the ventricular surface but they are most commonly located near the caudate nucleus just behind the foramen of Monro. On MR images, SENs appear as irregular nodules, signal is variable, usually hypointense to white matter on T2, because of calcification [2,4]. In neonates, these lesions are typically not calcified and appear hyperintense in comparison to unmyelinated white matter on T1-WI. Calcifications might increase with age. Variable enhancement of subependymal nodules are seen after contrast injection, but some nodules have no enhancement (Fig. 2).

Subependymal giant cell astrocytomas

SEGAs are located at or near the foramen of Monro (Fig. 3A). SEGAs are frequently calcified, and have heterogenous signal on MR images [3]. After contrast administration, these lesions show intense but inhomogenous enhancement (Fig. 3B). SEGAs also enlarge with the time. Associated obstructive hydrocephalus is common.

Histopathologic features

The main neuropathologic features of TSC include cortical and subcortical tubers, subependymal nodu­les (SENs), and subependymal giant cell astrocyto­mas (SEGAs) [18,24,30].

Tubers

Tubers are focal abnormalities of cortical architecture associated with TSC. Cortical tubers are found in the cerebral and cerebellar cortex, and subcortical white matter. Macroscopically, tubers are well-circumscribed, firm, pale, flat regions of cerebral cortex. They tend to be confined to a single gyrus or may span two or more gyri. In some cases, they may have lobar or even hemispheric distribution, sometimes even resulting in hemimegalencephaly. Tubers have a variable appearance with mushroom-shaped gyri and loss of the cortex-white matter junction. They are firmer and more pale than surrounding cortex or may exhibit irregular thickening and blurring of the cortical mantle and gray and white matter junction. Tubers can extend from the cortical surface deep into the subcortical white matter or can be confined to the cortical mantle. Their sizes range from a centimeter to several centimeters. Tubers may calcify or undergo cystic degeneration.
Microscopically, tubers are characterized by a marked disorganization of cortical lamination with aggregates of abnormal glial and dysplastic neuronal elements including giant cells [24,30] (Fig. 4A). Typically, the normal hexalaminar architecture of the cortex is lost or persist in only a rudimentary fashion. Other histologic features, often encountered, include vascular calcinosis with large aggregates of calcium distributed throughout the specimen.
The glial element consists of astrocytes of different size. Some enormous gemistocytic astrocytes with abundant, eosinophilic cytoplasm may be found (Fig. 4B). The tubers contain a hetrogenous population of neurons, some exhibiting bizarre and aberrant morphology, while others appear like normal cortical neurons (Fig. 4C). Dysmorphic neurons often show loss of radial orientation with respect to the pial surface, and exhibit an enlarged cell body with conspicuous Nissl substance (Fig. 4D). These dysmorphic neurons may reveal cytoskeletal abnormalities that are almost identical to those seen in the neurofibrillary tangle-containing neurons [30]. The tubers contain also cells of indeterminate neuronal versus glial phenotype with nucleotated nucleus and glassy amphophilic or eosinophilic cytoplasm (Fig. 4E). The most characteristic feature of tubers is the presence of enlarged cells, known as “balloon cells” (BCs) or “giant cells” (GCs) (Fig. 4F) [18,24,30]. These cells are similar to BCs found in sporadic focal cortical dysplasia (FCD) type 2B [11]. The maximal dimension of these cells is about 120 µm, but usually they range from 80 to 100 µm. GCs can be seen across the thickness of the tuber as well within the subcortical white matter or in the layer I. The dysmorphic neurons are interspersed with GCs throughout the thickeness of the tuber. GCs can be observed as the single cells or they are clumped together in clusters or chains, often near small vessels. Some of the GCs are multinucleated.
Cortical tubers are rarely found in the cerebellum. The cerebellar tubers exhibit marked disorganization of neuronal architecture with ectopic neurons in the molecular and granule cell layers and white matter. Giant cells, calcifications, gliosis and Rosenthal fibers could be also detected.

Immunohistochemistry

The glial cells exhibit the immunoexpression of glial fibrillary acidic protein (GFAP) across the thickness of tubers (Fig. 5A). Increased expression of the adhesion molecule CD44 is also observed. The recent studies have demonstrated enhanced numbers of CD68 immunoreactive microglial cells within tubers. Dysmorphic neurons express glutamate transporters, such as EAAC1, and neuronal markers i.e. neurofilament protein (Fig. 5B) or microtubule associated protein-2 (MAP2) and SMI32.
GCs are a highly heterogenous population with some extending MAP2 positive dendrites while others extend several small neurofilament positive processes, suggestive of axons. GCs are periodic-acid Schiff (PAS) positive [28].
The variable immunophenotype of cells creating cortical tubers suggests that they are atypical astrocytes, atypical neurons, or cells of indeterminate origin [24,28].

Subependymal nodules (SENs)

Subependymal nodules are present in about 80% of TSC patients and they are located around the wall of the lateral and third ventricle. These lesions deve­lop in fetal life and often degenerate or calcify during later life.
Macroscopically, SENs are nodular lesions, less then 1 cm in size. They occur singly or in rows (candle guttering) and smetimes they are completely calcified.
Microscopically, SENs consist of large cells, somewhat similar to the giant cells seen in tubers, and elongated glial cells. SENs are typically covered by a layer of ependyma and can exhibit extensive vascularization. SENs can grow over time and develop into subependymal giant cell astrocytomas [18,24,30].

Immunohistochemistry

The spindle cells of SENs are positive for GFAP. GCs exhibit immunostaining for both GFAP and neuronal markers i.e. neurofilament, synaptophysin and MAP2.

Subependymal giant cell astrocytoma (SEGA)

Subependymal giant cell astrocytomas (SEGAs) are the most common brain tumors occurring in about 5-10% of the TSC patients [18,24,30]. The progressive growth of enhancing lesions at the foramen of Monro in a TSC patient strongly suggests SEGA. They generally exceed 1 cm in diameter but can reach a greater size. SEGAs usually extend into lateral ventricle and can obstruct the foramen of Monro and flow of CSF, causing hydrocephalus.
Macroscopically, SEGAs are gray to pinkish red in color, and sometimes develop massive haemorrhages and calcifications.
Microscopically, SEGAs consist of a mixed cell popu­lation with dysmorphic glial cells and GCs. The glial cells are polygonal, epithelioid, gemistocytic or spindle shaped with marked pleomorphism, dense eosi­nophilic cytoplasm, eccentric nuclei, prominent nucleoli, and nuclear inclusions (Fig. 6A,B). They are arranged in sheets, clusters (Fig. 6C), or pseu­dorosettes (Fig. 6D). The giant cells contain regular nuclei and abundant, eosinophilic cytoplasm (Fig. 6E). The characteristic feature of SEGA is rich vascular stroma. SEGAs may contain numerous calcifications. Some mitotic figures (Fig. 6F) and foci of necrosis can be found. Inflammatory cell component, including mast cells and T lymphocytes can be detected [3].

Immunohistochemistry

Immunoreactivity for GFAP (Fig. 7A), neurofilament (Fig. 7B), S-100, neuron-specific enolase, and synaptophysin proteins suggest that these tumors contain both glial and neuronal cell types and the name subependymal giant cell tumor (SEGT) is suggested. SEGAs do not stain with HMB45 in contrast to AML and LAM. There was minimal expression of p53 and high expression of bax protein. SEGAs show low labeling index of Ki67 about 2.9% [12].
Other brain neoplasms, for example glioma, ependymoma, schwannoma, medulloblastoma, and ganglioglioma can be found in TSC, but they are rather coincidental than syndromic associations. In two cases sacral chordomas were found to contain TSC gene mutations [22].

Genetics

One third of patients have TSC history in their families, whereas two-thirds of all cases are caused by a “de novo” mutation or are the effect of the parental gonadal mosaicism.
The clinical signs of TSC are a result of mutations in either of two tumor suppressor genes: TSC1 (located on 9q34) or TSC2 (located on 16p13) [18]. About 400 different mutations for both genes have been described [6,7,8,18]. Proteins encoded by TSC1 and TSC2 genes, hamartin and tuberin, respectively, form a heterodimer which suppresses the mammalian target of rapamycin (mTOR), a major cell growth and proliferation controller. mTOR is a serine-threonine kinase that receives input from many various signaling pathways to activate translation, and thus increasing cell proliferation, and growth. It is established that within the TSC complex, TSC1 stabilizes TSC2.
The heterodimer formed by tuberin and hamartin exerts GTPase (GAP) – activity towards a small G protein, Ras-homoloque-enriched in brain (Rheb). Rheb is the direct target of the TSC1/TSC2 complex, leading to the inactivation of mTOR [5,13,18,19,25,31]. Rheb belongs to the family of G proteins, and, while being in its active GTP-bound state, stimulates mTOR, promoting protein synthesis and cell growth through phosphorylation of two downstream target proteins, S6K1 and 4E-BP1 (eukaryotic translation initiation factor 4E binding protein 1). S6K1 is a kinase that activates ribosomal subunit protein S6, leading to ribosome recruitment and protein translation. 4E-BP1 represses activity of eIF4E (eukaryotic translation ­initiation factor 4E) and, when phosphorylated by mTOR, releases eIF4E from its control (Fig. 8) [18].
Tuberin and hamartin also bind independently of the complex to a variety of other proteins and regulate many important proteins (Fig. 9A,B). Tuberin inhibition results in proapoptotic protein Bad activation and increased apoptosis [10]. Cortical tubers in TSC were shown to have caspase-8 and Fas support cytokine activated. TUNEL examination showed ongoing cell death in cortical tubers associated with TSC. TSC proteins play also important role in autophagy [16].
TSC2-Rheb-mTOR pathway was also shown to control axon guidance and growth in central nervous system [18,19]. Additionally, the activation of mTOR leads to an increase of vascular endothelial growth factor expression, promoting tumor growth. However, the clinical significance of these interactions remains unclear.
Formation of tumors in TSC is believed to fulfill Knudson’s two-hit model of tumorigenesis. According to this model, explaining the tumor-suppressor gene function, the inactivation of both alleles of either TSC1 or TSC2 genes is required for tumor formation [18]. A germline mutation (spontaneous or inherited) inactivates one allele of one of these two genes. Somatic, second hit mutations affecting heterozygous loci are referred to as loss of heterozygosity (LOH). In TSC, LOH is commonly found in kidney angiomyolipomas, but less frequently in cardiac rhabdomyomas, rarely in subependymal giant cell astrocytomas (SEGAs) and extremely rarely in cortical tubers [18]. Therefore, several hypotheses have been mooted to explain brain lesion pathogenesis in TSC. Many reports indicate that post-translational inactivation of TSC1/TSC2 complex arise through Akt kinase activation. Akt, a downstream effector of PI3K (phosphoinositide-3-OH kinase) is known to activate mTOR-dependent translation. The other mechanism of tumorigenesis in TSC is inactivation of the hamatrin-tuberin complex after phosphorylation by various kinases, such as extracellular signal-regulated kinase (ERK), which was found in subependymal giant cell astrocytomas and cardiac rhabdomyomas [13]. TSC1-TSC2 complex stability may be also influenced by death associated protein kinase (DAPK). DAPK functions in a wide range of biological pathways, including TNF-regulated cell death, stress-induced apoptosis, and autophagy [10,16]. DAPK can mediate an inactivating phosphorylation of TSC2 and reduce its bioactivity after growth factor signaling. Consistent with these results, manipulation of DAPK by transfection or siRNA demonstrates that DAPK acts as a positive mediator of the mTORC1 translation pathway in response to growth factor stimulation.
Recently, gene expression profiling of SEGAs showed other genes possibly involved in these tumors development. Some genes implicated in tumorigenesis and nervous system development, like ANXA1, GPNMB, LTF, RND3, S100A11, SFRP4, and NPTX1 are likely to be mTOR effector genes in SEGA, as their expression was modulated by an mTOR inhibitor, rapamycin, in SEGA-derived cells [13,29].
LOH has been reported in many TSC-related lesions, however it not found with the same incidence in all tissues and organs. LOH is more frequent in renal angiomyolipomas, less common in subependymal giant cell astrocytomas, and almost absent in cortical tubers [5,18]. Therefore, it is likely that haploinsufficiency may contribute to the development of lesions in some organs, most importantly in brain lesions [18].

Conclusions and future direction

Rapamycin and its analogs are currently tested in several clinical trials in TSC. Various preclinical models showed that rapamycin treatment reduces TSC-related tumors, including brain, skin, and kidney tumors [23]. In clinical studies, oral rapamycin therapy lead to the regression of such hamartomas as SEGA, kidney AML [9,20,21] and LAM in TSC patients. Additionally, systemic rapamycin treatment has been found to be an antiepileptic medication in cases of epileptogenic cortical dysplasia and reduce seizures and cognitive defects in mouse models of TSC [23].
The understanding of TSC pathogenesis may provide useful data for neuroscientists working on brain tumors, epilepsy and neuronal migration disorders. It is yet known, that normal function of TSC1 and TSC2 genes and proteins is very important for brain deve­lopment, because it regulates cortical lamination, axon outgrowth, and cell size. However, still many issues require further studies. Firstly, understanding how loss of TSC1 or TSC2 influences cell migration may explain the origin of disordered lamination in tubers and cortical dysplasia. Secondly, defining mechanisms that are responsible for conversion from SEN to SEGA and then the uncontrolled growth of SEGAs could yield new strategies for brain tumors. Finally, defining the role of TSC1 or TSC2 in infantile spasms generation and intractable epilepsy would provide novel approaches to epilepsy management.

References

 1. Ahlsén G, Gillberg IC, Lindblom R, Gilberg C. Tuberous sclerosis in Western Sweden. A population study of cases with early childhood onset. Arch Neurol 1994; 51: 76-81.  
2. Baskin HJ Jr. The pathogenesis and imaging of the tuberous sclerosis complex. Pediatr Radiol 2008; 38: 936-952.  
3. Boer K, Jansen F, Nellist M, Redeker S, van den Ouweland AM, Spliet WG, van Nieuwenhuizen O, Troost D. Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. Epilepsy Res 2008; 78: 7-21.  
4. Braffman BH, Bilaniuk LT, Naidich TP, Altman NR, Post MJ, Quencer RM, Zimmerman RA, Brody BA. MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review. Radiology 1992; 183: 227-238.  
5. Chan JA, Zhang H, Roberts PS, Jozwiak S, Grajkowska W, Lewin­-Kowalik J, Kotulska K, Kwiatkowski DJ. Pathogenesis of tuberous clerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leades to mTOR activation. J Neuropathol Exp Neurol 2004; 63: 1236-1242.  
6. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006; 355: 1345-1356.  
7. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372: 657-668.  
8. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001; 68: 64-80.  
9. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490-498.
10. Freilinger A, Rosner M, Krupitza G, Nishino M, Lubec G, Korsmeyer SJ, Hengstschläger M. Tuberin activates the proapoptotic molecule BAD. Oncogene 2006; 25: 6467-6479.
11. Grajkowska W, Kotulska K, Matyja E, Larysz-Brysz M, Mandera M, Roszkowski M, Domańska-Pakieła D, Lewik-Kowalik J, Jóźwiak S. Expression of tuberin and hamartin In tuberous sclerosis complex-associated and sporadic cortical dyspalsia of Taylor’s balloon cell type. Folia Neuropathol 2008; 46: 43-48.
12. Gyure KA, Prayson RA. Subependymal giant cell astrocytoma: a clinicopathologic study with HMB45 and MIB-1 immunohistochemical analysis. Mod Pathol 1997: 10: 313-317.
13. Jozwiak J, Grajkowska W, Kotulska K, Jozwiak S, Zalewski W, Zajaczkowska A, Roszkowski M, Slupianek A, Wlodarski P. Brain tumor formation in tuberous sclerosis depends on Erk activation. Neuromolecular Med 2007; 9: 117-127.
14. Jóźwiak S, Migone N, Ruggieri M. The Tuberous Sclerosis Complex. In: Ruggieri M, Castroviejo IP, DiRocco C (eds.). Neurocutaneous Disorders. Springer, Wien, NewYork 2008; pp. 181-227.
15. Jozwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol 2000; 15: 652-659.
16. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010; 584: 1287-1295.
17. Jurkiewicz E, Jozwiak S, Bekiesinska-Figatowska M, Pakula­-Kosciesza I, Walecki J. Cyst-like cortical tubers in patients with tuberous sclerosis complex: MR imaging with the FLAIR sequence. Pediatr Radiol 2006; 36: 498-501.
18. Kwiatkowski DJ, Whittemore VH, Thiele EA. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley VCH, Weinheim 2010.
19. Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 2005; 14: 251-258.
20. Lam C, Bouffet E, Tabori U, Mabbott D, Taylor M, Bartels U. Rapamycin (sirolimus) in tuberous sclerosis associated pedia­tric central nervous system tumors. Pediatr Blood Cancer 2009; 54: 476-479.
21. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O’Reilly T. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009; 15: 1612-1622.
22. Lee-Jones L, Aligianis I, Davies PA, Puga A, Stemmer-Rachamimov A, Ramesh V, Sampson JR. Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2. Genes Chromosomes Cancer 2004; 41: 80-85.
23. Ljungberg MC, Sunnen CN, Lugo JN, Anderson AE, D'Arcangelo G. Rapamycin suppresses seizures and neuronal hyphertrophy in a mouse model of cortical dysplasia. Dis Model Mech 2009; 2: 389-398.
24. Mizuguchi M, Takashima S. Neuropthology of tuberous sclerosis complex. Brain Dev 2001; 23: 508-515.
25. Nie D, Di Nardo A, Han JM, Baharanyi H, Kramvis I, Huynh T, Dabora S, Codeluppi S, Pandolfi PP, Pasquale EB, Sahin M. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci 2010; 13: 163-172.
26. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998; 13: 624-628.
27. Rott HD, Lemcke B, Zenker M, Huk W, Horst J, Mayer K. Cyst-like cerebral lesions in tuberous sclerosis. Am J Med Genet 2002; 111: 435-439.
28. Talos DM, Black PM, Jensen FE. Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Ann Neurol 2008; 63: 454-465.
29. Tyburczy ME, Kotulska K, Pokarowski, P Mieczkowski J, Kuchar­ska J, Grajkowska W, Roszkowski M, Jozwiak S, Kaminska B. Novel Proteins Regulated by mTOR in Subependymal Giant Cell Astrocytomas of Patients with Tuberous Sclerosis Complex and New Therapeutic Implications. Am J Pathol 2010; 176: 1878-1890.
30. Vinters HV, Miyata H. Neuropathologic features of tuberous sclerosis. In: McLendon RE, Rosenblum MK, Bigner DD (eds.). Russel and Rubinsten’s Pathology of Tumors of the Nervous System. 7th ed. Hodder Arnold Publication, London 2006; pp. 955-969.
31. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003, 5: 578-581.
Copyright: © 2010 Mossakowski Medical Research Centre Polish Academy of Sciences and the Polish Association of Neuropathologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.